Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Carboplatin vs Gemcitabine in Advanced NSCLC
NCT00190710Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Mar 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00190710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190710.